Navigation Links
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Date:1/4/2012

NEW YORK, Jan. 4, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at JP Morgan's 30th Annual Healthcare Conference, being held January 9th-12th in San Francisco, California.  Mr. Bentsur's presentation is scheduled to take place on Thursday, January 12, 2012 at 10:00 a.m. PT (1:00pm ET). 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
7. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
10. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... ... North Carolina, and engages Timothy Reinhardt to manage the new site. , Tim ... Pfizer Inc, with his most recent role as the Director of Manufacturing and ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports ... a disease, bringing new hope for prospective parents who are challenged with costs ... back the World Health Organization’s designation in hopes of changing the way health ...
(Date:6/22/2017)... , ... June 22, 2017 , ... The first human ... 20 years until the first data on cross-contamination of human cell lines with HeLa ... an increasing issue in cell culture labs and is associated with dramatic consequences for ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... board of directors has formed a Higher Education Entrepreneurship Advisory Committee to implement ... institution presidents and other high-ranking representatives from 35 higher education institutions across the ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):